Jiangxi Synergy Pharmaceutical Adjusts Valuation Amid Ongoing Financial Challenges

Jiangxi Synergy Pharmaceutical Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, indicating a transition from a previously assessed expensive status to a fair valuation. Key financial indicators reveal a P/E ratio of 36, alongside a Price to Book Value of 1.44. The company's EV to EBIT stands at 55.92, while the EV to EBITDA is recorded at 22.49. Additionally, Jiangxi Synergy maintains a dividend yield of 0.50%, with a Return on Capital Employed (ROCE) of 2.45% and a Return on Equity (ROE) of 3.97%. Despite being net-debt free, the company has faced challenges, including a decline in operating profit margins and negative results over the last eight consecutive quarters. The annual growth rate for net sales has been 11.76%, but operating profit has shown a decrease of 3.98% over the past five years. This evaluation adjustment highlights the ongoing trends within Jiangxi Synergy Pharmaceutical Co., Ltd. and its current market positioning. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.